Lonza expands capsule manufacturing capacity in India and China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
This facility marks a significant milestone in transforming the global food industr
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Final decision from the European Commission is anticipated within the coming months
Subscribe To Our Newsletter & Stay Updated